ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES

Objective: to investigate the immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatic diseases (RD).

Subjects and methods. The prospective open-label comparative study enrolled 133 people (102 (76.7%) women and 31 (23.3%) men) aged 23 to 76 years, including 79 patients with rheumatoid arthritis (RA), 16 with systemic sclerosis, and 7 with dermatomyositis/polymyositis, as well as 31 subjects without systemic inflammatory RD (a control group), who had a recent history of at least two cases of lower respiratory tract infections (bronchitis, pneumonia). At their inclusion, all the patients with RD were receiving ant-inflammatory therapy, including 52 taking methotrexate (MT), 14 – leflunomide (LEF), and 13 – MT + tumor necrosis factor-α (TNF-α) inhibitors. The 23-valent polysaccharide pneumococcal vaccine Pneumo-23 (Sanofi Pasteur, France) was administered in a single dose of 0.5 ml subcutaneously during continuous MT or LEF therapy for the underlying disease or 3–4 weeks before the use of TNF-α inhibitors. Clinical examinations of the patients and conventional laboratory studies were performed during control visits (1, 3, and 12 months after vaccination). The serum levels of anti-pneumococcal capsular polysaccharide antibodies were measured in 102 patients by enzyme immunoassay using commercial VaccZymeTM Anti-PCP IgG Enzyme Immunoassay kits (The Binding Site Group Ltd, United Kingdom).

Results and discussion. No clinical and radiological symptoms of pneumonia were recorded in any case during the follow-up period of 12 months. The patients with RD and the control group showed a significant, more than double increase in anti-pneumococcal antibodies 12 months following vaccination. Vaccination was well tolerated: 90 (68%) patients displayed no adverse events; 37 (28%) had pain, cutaneous swelling and hyperemia up to 2 cm in diameter at the site of injection for vaccination;6 (4%) had low-grade fever. There were no episodes of a RD exacerbation or any new autoimmune disorders during the follow-up period.

Conclusion. The findings were suggestive of the sufficient immunogenicity and good tolerability of 23-valent pneumococcal vaccine in patients with RD.

1. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012;66(12):1177–81. doi: 10.1136/jech-2011-200168

2. Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among U.S. veterans with rheumatoid arthritis. Arthritis Care Res. 2014;66(7):990–7. doi: 10.1002/acr.22281

3. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):353–61. doi: 10.1002/acr.21812

4. Koivuniemi R, Leirisalo-Repo M, Suomalainen R, et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006;35:273–6. doi: 10.1080/03009740600556258

5. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414–22. doi: 10.1136/ard.2010.137216

6. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39. doi: 10.1002/acr.21641

7. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100. doi: 10.1093/cid/cit684

8. Lanternier F, Henegar C, Mouthon L, et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis. 2008;67(7):1047. doi: 10.1136/ard.2007.081703

9. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(6):837–8. doi: 10.1136/ard.2006.060285

10. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–8. doi: 10.1136/annrheumdis-2013- 204223

11. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569–81. doi: 10.1002/art.27584

12. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011 Mar;70(3):476–81. doi: 10.1136/ard.2010.136929

13. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N EngI J Med. 1975;292:344–7. doi: 10.1056/NEJM197502132920706

14. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403. doi: 10.1056/NEJM197502202920807

15. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–6. doi: 10.1136/annrheumdis-2012-202658

16. Bingham CO 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015 May; 74(5):818–22. doi: 10.1136/annrheumdis-2013-204427

17. Bengtsson C, Kapetanovich MC, Kallberg H, et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2010 Oct;69(10):1831–3. doi: 10.1136/ard.2010.129908

18. Hmamouchi I, Winthrop K, Launay O, et al. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015 Mar 17;33(12):1446–52. doi: 10.1016/j.vaccine.2015.01.065

19. Костинов МП, Тарасова АА. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Москва: МДВ; 2009. 252 с. [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniyakh [Vaccine influenza and pneumococcal infection in autoimmune diseases]. Moscow: MDV: 2009. 252 p.].

20. Kapetanovich MС, Saxne T, Sjoholm A, et al. Influence of methotrexat, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45:106–11. doi: 10.1093/rheumatology/kei193

21. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013 Aug;72(8):1362–6. doi: 10.1136/annrheumdis-2012-202658

22. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices: Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR. 2010;59:1102–6.

23. Bijl M, Agmon-Levin N, Dayer JM, et al. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev. 2012;11(8):572–6. doi: 10.1016/j.autrev.2011.10.015